IMR Press / FBS / Volume 2 / Issue 3 / DOI: 10.2741/S114

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

CD4 (+)CD25 (+)Foxp3 (+) regulatory T cells and hematologic malignancies
Show Less
1 Department of Pathology, University of Utah, Salt Lake City, UT, USA
2 ARUP Laboratories, Salt Lake City, UT
3 Division of Hematology and Bone Marrow Transplant, Department of Internal Medicine, University of Utah, Salt Lake City, UT

*Author to whom correspondence should be addressed.

Academic Editor: Xiao-Feng Yang

Front. Biosci. (Schol Ed) 2010, 2(3), 980–992;
Published: 1 June 2010
(This article belongs to the Special Issue Homeostasis and therapeutical potential of CD4)

Regulatory T cells (Tregs) are an immunosuppressive T cell subset that functions to prevent autoimmunity and to regulate physiologic immune reactions. Tregs are also present in the tumor microenvironment and appear to play an important role in the pathophysiology of malignant processes. Available data suggests that this role is context-dependent, as a higher density of tumor infiltrating Tregs at diagnosis may be associated with either a positive or a negative clinical outcome. Negative prognostic associations are found primarily in solid tumors such as ovarian carcinoma, while positive associations have been reported in various lymphomas, most prominently in those of germinal center (GC) B cell derivation. Most of these observations are correlative, however, as mechanistic studies have lagged behind descriptive observations because of a lack of informative animal models. Nonetheless, the available data are intriguing and provide compelling support for the hypothesis that Tregs are pathobiologically relevant. This review focuses on studies of the role of CD4 (+)CD25 (+)FOXP3 (+) Tregs in hematopoietic alignancies and clonal myeloid neoplasms.

Back to top